Magenta’s match

Be the Match BioTherapies’ first ever equity investment was motivated by desire to back a company that shared its goal of helping transplant patients achieve better outcomes, rather than by a planned strategic shift toward financing early stage innovation.

Be the Match, a subsidiary of the National Marrow Donor Program (NMDP), participated in Magenta Therapeutics Inc.’s $50 million series B round announced May 2. GV led the round, which included Atlas Venture, Third Rock Ventures, Partners Innovation Fund, Access Industries and Casdin Capital. ...